AtaiBeckley Inc. (NASDAQ:ATAI<\/strong>) is one of the best multibagger penny stocks to invest in<\/strong>. On March 27, Deutsche Bank initiated coverage of AtaiBeckley Inc. (NASDAQ:ATAI) with a Buy rating and a $12 price target.<\/p>\n Pixabay\/Public domain<\/p>\n The Buy rating underlines the investment bank\u2019s confidence in the company\u2019s long-term prospects as a leader in the emerging field of psychedelic medicine. BPL-003 and VLS-01 are Atai Life Sciences candidate drugs in the treatment of mental health conditions under development to address resistant depression.<\/p>\n Deutsche Bank expects the program to leverage Spravato\u2019s commercial model to address resistant depression. The bank is also confident that psychedelic therapies will go mainstream in the next few years. The optimism comes amid expectations that Atai will deliver top-line Phase 2 data for VLS-01 in the second half of the year. The company is also expected to deliver Phase 2a Part 4 data for BPL-003 in the fourth quarter.<\/p>\n AtaiBeckley Inc. (NASDAQ:ATAI) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for mental health disorders, particularly using psychedelic compounds and other psychoactive drugs. Founded in 2018, the company aims to heal mental health conditions like depression, anxiety, and addiction through a portfolio of therapeutic candidates.<\/p>\n While we acknowledge the potential of ATAI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the\u00a0best short-term AI stock<\/strong>.<\/p>\n<\/div>\n<\/div>